Editas Medicine, Inc. vs Pfizer, Inc. — Stock Comparison

Editas Medicine, Inc. (EDIT) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.

Q·Score Winner
Pfizer, Inc.
PFE6.4/10vs 4.2/10

Pfizer, Inc. clearly outscores Editas Medicine, Inc. on Q·Score (6.4 vs 4.2 out of 10), led by Quality (6.4 vs 0.2) and Health (7 vs 5.2). Editas Medicine, Inc. scores higher on Sentiment, reflecting stronger analyst and market sentiment. Analyst consensus targets imply greater upside for EDIT (+114.8%) than for PFE (+15.8%).

Price Performance

Normalised to 100 at period start — shows relative performance.

Loading…
EDITPFE

Q·Score Breakdown

4.2
Bearish
Overall
6.4
Neutral
0.2
Quality
6.4
5.2
Health
7
4.5
Growth
5.1
6.9
Valuation
7.7
5.4
Sentiment
5.3
EDIT

Consensus analyst target of $5.78 is 115% above current price.

currently unprofitable (-282% margin).

PFE

Forward P/E of 8.9× is low relative to sector peers.

earnings contracting 10% year-over-year.

Analyst Consensus

Neutral
+114.8%
Target $5.78
9 analysts
Neutral
+15.8%
Target $29.19
27 analysts

Fundamentals

EDIT
PFE
Trailing P/E
19.2×
-2.9×
Forward P/E
8.9×
-281.59%
Profit Margin
11.83%
-109.24%
Gross Margin
74.80%
-326.07%
ROE
8.31%
-39.20%
Revenue Growth
5.40%
Earnings Growth
-10.10%
2.10
Beta
0.29
Dividend Yield
6.61%
$413M
Market Cap
$143.7B
52-Week Range
EDIT
$236% of range$5
PFE
$2337% of range$29

Frequently Asked Questions

EDIT vs PFE: which stock scores better overall?

Based on Q·Score, Pfizer, Inc. (PFE) scores 6.4/10 versus Editas Medicine, Inc. (EDIT) at 4.2/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.

Which has better revenue growth: EDIT or PFE?

Pfizer, Inc. (PFE) scores higher on Growth (5.1/10 vs 4.5/10). Editas Medicine, Inc. reports revenue growth (-39.2% YoY) while Pfizer, Inc. reports (5.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.

Is EDIT or PFE more attractively valued?

Pfizer, Inc. (PFE) scores higher on Valuation (7.7/10 vs 6.9/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.

What do analysts say about EDIT vs PFE?

There are 9 analysts covering EDIT with a consensus price target of $5.78, and 27 analysts covering PFE with a consensus target of $29.19. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.

Which is more profitable: EDIT or PFE?

Pfizer, Inc. (PFE) scores higher on Quality (6.4/10 vs 0.2/10). Net profit margin: EDIT at -281.6%, PFE at 11.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.

Which has stronger financial health: EDIT or PFE?

Pfizer, Inc. (PFE) scores higher on Financial Health (7/10 vs 5.2/10). Market beta: EDIT at 2.10, PFE at 0.29. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.

What are the market caps of EDIT and PFE?

Editas Medicine, Inc. (EDIT) has a market capitalisation of $413M, while Pfizer, Inc. (PFE) has a market cap of $143.7B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.

Do EDIT or PFE pay dividends?

EDIT does not currently pay a dividend, while PFE pays a dividend yield of 6.61%. Dividend yields fluctuate with share price and company payout decisions.

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →

Data provided by Yahoo Finance ·  Updated on each page load ·  For informational purposes only · Not financial advice · Quantify.biz © 2026